【国金证券：港股创新药的“估值扩张弹性、空间”或强于A股】金十数据4月5日讯，国金证券研报认为，AI赋能之下，研发周期缩短、成本下降、效率提升等，均将从中期维度提振创新药企的IRR水平，板块或将有望迎来新的成长逻辑。全球医药产业投融资活动回暖，有利创新药企融资现金流改善，在行业投融资周期的显著上行阶段，创新药板块在资本市场上的表现往往都较为出色。静待财政发力，创新药企业存在毛利率修复空间，一方面，“丙类目录”为代表的行业政策发布在即或是板块估值和情绪修复的重要催化，另一方面，“社保注资”或是财政发力的选项之一，从而能够减轻医保支付压力，带动基本医疗保险支出增速持续回暖，创新药板块的营收增速将有望迎来向上拐点，毛利率亦有望修复。港股创新药的“估值扩张弹性、空间”或强于A股。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.